Coherus Oncology Q3 2026 Results: Net Loss of $39.3M, Loss Widens
Coherus Oncology, Inc. reported 154,538,277 shares of common stock outstanding as of October 31, 2026. The company expressed substantial doubt about its ability to continue as a going concern due to expected future operating losses and negative cash flows, following the divestiture of its UDENYCA franchise.
- Key figure
- Net loss $39.3M